tapebrief
JNJ · Q2 2025

JNJ · Q3 2025 Earnings

Bullish

Johnson & Johnson

Reported October 14, 2025

30-second summary

J&J posted $24.0B revenue (+6.8% YoY) and $2.80 adjusted EPS, with Oncology +19.2% operational and MedTech operationally accelerating to 5.7% ex-A&D. Management raised FY2025 operational sales guidance midpoint by 30bps to 5.1% (~$300M) and reaffirmed adjusted EPS at $10.85, while the CFO took the unusual step of telling analysts their 2026 consensus of 4.6% revenue growth and $11.39 EPS is below internal expectations — implying >5% growth and up to $0.05 EPS upside. Tone has shifted from "growing through Stelara" to "powerful new era of growth," with the orthopaedics separation now the next strategic catalyst.

Headline numbers

EPS

Q3 FY2025

$2.80

Revenue

Q3 FY2025

$23.99B

+6.8% YoY

Gross margin

Q3 FY2025

69.6%

Operating margin

Q3 FY2025

31.2%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$23.99B+6.8%$23.74B+1.1%
EPS$2.80—$2.77+1.1%
Gross margin69.6%—67.9%+170bps
Operating margin31.2%—27.3%+390bps

Guidance

Johnson & Johnson raised full-year operational and reported sales growth guidance by 30 bps at midpoint, while reaffirming EPS and operating margin targets.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Effective Tax RateFY202517.5% to 18.0%—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Reported Sales Growth
FY2025
5.1% to 5.6%, midpoint 5.4%5.4% to 5.9%, midpoint 5.7%+0.3 pts midpoint (5.4% → 5.7%)Raised
Operational Sales Growth
FY2025
4.5% to 5.0%, midpoint 4.8%4.8% to 5.3%, midpoint 5.1%+0.3 pts midpoint (4.8% → 5.1%)Raised

Reaffirmed unchanged this quarter: Adjusted Operational EPS ($10.68, 7% growth), Non-GAAP EPS ($10.80 to $10.90, midpoint $10.85)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Innovative Medicine$15.563B+6.8%
MedTech$8.43B+6.8%
Oncology$6.529B+21.3%
Immunology$4.168B-9.8%
Innovative Medicine Adjusted Operational Growth (ex-A&D)3.7%—
MedTech Adjusted Operational Growth (ex-A&D)5.7%—
Darzalex Revenue Growth21.7%—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
U.S.$13.708B+6.2%
Europe$5.44B+10.7%
Western Hemisphere excluding U.S.$1.231B+4.9%
Asia-Pacific, Africa$3.614B+4.0%
Adjusted Operational Sales Growth (ex-A&D)4.4%—
International Revenue Growth (operational)4.4%—
U.S. Revenue Growth (operational)6.2%—
Adjusted Effective Tax Rate19.4%—
GAAP Effective Tax Rate31.2%—

Management tone

Q1 FY2025: Stelara navigation → Q2 FY2025: growth through LOE → Q3 FY2025: "powerful new era of growth" → forward: 2026 upside telegraphed

Stelara has moved from a problem to a closed chapter across three quarters. Q1 FY2025 framing was about navigating the LOE; Q2 FY2025 was about proving J&J could grow through it; this quarter Joaquin Duato declared it "unequivocally answered" and Joe Wolk said Stelara is "increasingly in the rearview mirror." The verbatim anchor: "Some were not convinced we could grow through the loss of exclusivity of Stellara, but we were confident and we have now unequivocally answered that question." This matters because it severs the link between LOE pressure and forced M&A — management is now explicit that large speculative deals are off the table.

The 2026 setup has shifted from cautious-TBD to active pre-guidance. Last quarter the CFO expressed personal confidence in exceeding the 2023 long-range targets; this quarter he went further and named the consensus number he disagrees with: "it appears the current revenue consensus of 4.6% growth in your models for 2026 is lower than we project, which we believe in total will exceed 5%... there appears to be some upside to the current adjusted earnings per share consensus of $11.39, perhaps as much as $0.05." J&J does not usually call out analyst models by number. This is a pre-print signal that January's formal guide will be above street.

Pipeline framing has hardened from "progression" to "proof." Joaquin Duato: "This is more than just another strong quarter. It is proof that our momentum is building and that our impact is accelerating." Two quarters ago oncology was the aspirational anchor; one quarter ago the $50B-by-2030 became a base case; this quarter management is using current performance (Oncology +19.2% operational, Darzalex +19.9% operational, Tremfya +40%) as the load-bearing evidence that the acceleration is structural.

Orthopaedics separation enters as the next strategic story. New this quarter: management quantified +75bps of margin and revenue uplift for the remaining MedTech, framing the spin as a focus accelerator on cardiovascular and robotics rather than a capital event. The phrase "Following the separation, Johnson & Johnson will retain a leadership position in our six core growth areas" signals the spinoff timing is near and post-separation J&J is the entity to model.

The hedging has receded. Joe Wolk's "We are as confident as we have been in recent memory about the future" is unusually emphatic for a CEO. The only meaningful caveats this quarter were on talc litigation (Daubert ruling expected Q1 FY2026), tariffs ("what we know today"), and the MFN dialogue — all external, none internal to the operating model.

Recurring themes management leaned on this quarter:

Portfolio momentum across oncology, immunology, neuroscience with double-digit brand growthTrenfaya and Darzalex as major growth drivers; Trenfaya potential >$10B assetOrthopedics separation to sharpen focus on higher-growth cardiovascular and robotic surgeryStrong cash generation ($14B YTD free cash flow) supporting innovation investment and shareholder returnsMedTech acceleration with cardiovascular (Shockwave, Abiomed, electrophysiology) and vision outperformance2026 expected to exceed 5% revenue growth with EPS upside vs. consensus

Risks management surfaced:

Talc litigation—Daubert motions pending, expected Q1 2026 rulingMacroeconomic factors impacting MedTech margin (21% vs. 24.1% prior year)China VBP (volume-based pricing) negative impact on Surgery segmentCurrency headwinds (~640 bps Stellara headwind; company remains cautious on FX movements)Tariff uncertainty—guidance assumes 'what we know today as it relates to tariffs'

Q&A highlights

Danielle Antalpi · UBS

On post-ortho spin margin expansion target of 75 basis points: Does this seem light given the high-growth cardio and surgical mix, and what are the puts and takes to this number?

Management clarified that 75 bps is a multi-year target; 2025 margins could improve closer to 100 bps. As higher-growth acquisitions (Abiomed, Shockwave) mature and margin improvement initiatives progress, the impact becomes more muted over the longer term.

75 basis points margin improvement target (multi-year)2025 could see closer to 100 bps margin improvementMargin impact becomes muted as higher-growth businesses matureAbiomed and Shockwave have higher growth profiles

Asad Haider · Goldman Sachs

How will J&J balance capital allocation to sustain acceleration in innovative medicines and push MedTech toward 5%-7% targets? Also, what are biggest disconnects in consensus models for innovative medicines sales growth in 2026?

Management confirmed pipeline and portfolio investment is priority #1. Highlighted multiple growth drivers including Tramfaya (40% growth), Spravato, Ribrevan/Lasclus, Inlexo, and Icotrikinra as $5B+ assets. Emphasized strength in pharma ex-Stelara (16% growth) and that they don't need large M&A to hit high end of growth targets.

Pharmaceutical business ex-Stelara grew 16% in Q3Pharma business is $50B+ in sizeTramfaya: 40% growth, 50% share of IL-23s in ulcerative colitisMultiple pipeline assets expected to be $5B+ brands

Chris Schott · J.P. Morgan

Framework for Most Favored Nation (MFN) agreements with administration on new launches and Medicaid, and J&J's approach to policy dynamics?

Management stated ongoing dialogue with administration, seeking common ground on priorities including patient access to innovation, preventing foreign free-riding on U.S. innovation, maintaining U.S. life sciences leadership, and domestic manufacturing. Announced $55B U.S. investment plan over 4 years to manufacture advanced medicines domestically. No specifics on MFN discussions but expressed optimism.

$55 billion planned investment in U.S. over next 4 yearsAll advanced medicines used in U.S. will be manufactured in U.S.Open dialogue with administration since before day oneFocus on American patient access, preventing foreign free-riding, and U.S. manufacturing jobs

Shagun Singh · RBC

What gets J&J to exceed the 5%-7% growth guidance range given many businesses growing in double digits? Why is 5% a good number for 2026 with easy comps?

Management reiterated commitment to 5%-7% guidance but stated they are 'striving for something better.' For 2026 specifically, they will face continued Stelara erosion, portfolio discounting, ortho headwinds, but expect improvements from electrophysiology expansion. Noted clear disconnect in analyst models for 2026; more details in January.

5%-7% guidance commitment from 2023Striving for better than guidance2026 will see additional Stelara erosion and portfolio discountingAnalyst models show clear disconnect vs. management expectations

Bommel de Bon · Guggenheim Securities

Near-term Inlexo uptake dynamics (buy-and-bill vs. permanent J-code wait), and longer-term data/regulatory updates within 12-18 months to expand addressable population?

Management reported strong initial physician receptivity and insertions despite buy-and-bill model; expects permanent J-code catalyst in April. Broad Phase 3 program underway for BCG-experienced, BCG-relapsed, and frontline settings. TAR-210 next-generation device in development with 90%+ response rates expected. ESMO data on neoadjuvant combination with citrelumab coming.

Inlexo positioned as $5B+ asset50%+ complete response rates without re-inductionJ-code reimbursement expected April 2026Multiple Phase 3 studies ongoing (BCG-experienced, BCG-relapsed, frontline)

Answers to last quarter's watch list

TAR200 approval and launch trajectory — Now branded Inlexo. Management called it a $5B+ asset with 50%+ complete response rates and described "strong initial physician receptivity and insertions" despite operating under buy-and-bill, with the permanent J-code catalyst in April 2026. Phase 3 expansions underway across BCG-experienced, BCG-relapsed, and frontline settings. The TAR-210 next-gen device extends the franchise. No script-level disclosure yet, but commercial launch is clearly underway.
Resolved positively
Stelara erosion shape — Immunology segment fell 9.8% to $4.17B, reflecting the ongoing biosimilar curve. Importantly, Innovative Medicine ex-Stelara still grew 16% (consistent with Q2 FY2025's 15.5%), and management said the LOE is now "increasingly in the rearview mirror" and "unequivocally answered." The erosion is tracking expectations rather than accelerating.
Resolved positively
MedTech operating margin progress — The FY ~300bps operating margin improvement was reaffirmed; consolidated operating margin came in at 31.2%. Tariff and China VBP commentary remained, but management did not flag any incremental deterioration. The 75bps post-spin uplift adds a second margin lever. Status: Continue monitoring (Q4 FY2025 still has to do the heavy lifting).
Rybrevant/Lazcluze CRL resolution — Management cited Rybrevant/Lazcluze among multiple $5B+ pipeline assets and did not flag any further regulatory delay; the franchise was discussed as a contributor to oncology growth rather than a problem to resolve.
Resolved positively
MFN policy inclusion in guidance — Still excluded from guidance. Management would not give specifics on MFN negotiations and pivoted to the $55B U.S. manufacturing commitment. No quantified impact disclosed.
Continue monitoring

What to watch into next quarter

Q4 FY2025 effective tax rate — Adjusted tax rate ran 19.4% in Q3 FY2025 vs. new full-year guide of 17.5%–18.0%; 9M is already at 18.0%, so Q4 needs ~17% or below to land mid-range. Watch whether the EPS reaffirmation holds.

January 2026 formal guide vs. CFO's pre-signal — Joe Wolk telegraphed >5% revenue growth and up to $0.05 above the $11.39 EPS consensus. The January print is now a hard test of management credibility; anything at or below 5% revenue will be read as a walk-back.

Orthopaedics separation timing and stranded-cost disclosure — Management is now talking actively about the post-separation J&J; watch for the formal timeline, dividend posture confirmation ("we do not expect any change... mindful of any impact from stranded costs"), and the +75bps margin quantification getting tightened.

Inlexo Q4 FY2025 script trajectory and J-code April 2026 setup — First quarter of full commercial launch; any disclosure of institutional adoption or insertion volume before the J-code catalyst will be a leading indicator on the $5B+ peak claim.

Stelara Q4 FY2025 dollar print — Immunology was down 9.8% in Q3 FY2025; watch whether the erosion stabilizes or steepens into year-two of biosimilar competition.

Talc Daubert ruling (Q1 FY2026) — Management flagged the expected ruling; this is the most material legal overhang and could move quickly.

Sources

  1. Johnson & Johnson Q3 FY2025 Earnings Press Release (Exhibit 99.2), filed October 14, 2025 — https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/a2025q3exhibit992.htm
  2. Johnson & Johnson Q3 FY2025 Earnings Call — prepared remarks (Joaquin Duato, Joe Wolk) and Q&A session.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.